341 related articles for article (PubMed ID: 30858151)
1. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
[TBL] [Abstract][Full Text] [Related]
2. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
[TBL] [Abstract][Full Text] [Related]
3. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
Rotolo A; Caputo VS; Holubova M; Baxan N; Dubois O; Chaudhry MS; Xiao X; Goudevenou K; Pitcher DS; Petevi K; Kachramanoglou C; Iles S; Naresh K; Maher J; Karadimitris A
Cancer Cell; 2018 Oct; 34(4):596-610.e11. PubMed ID: 30300581
[TBL] [Abstract][Full Text] [Related]
5. iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo .
Bassiri H; Das R; Guan P; Barrett DM; Brennan PJ; Banerjee PP; Wiener SJ; Orange JS; Brenner MB; Grupp SA; Nichols KE
Cancer Immunol Res; 2014 Jan; 2(1):59-69. PubMed ID: 24563871
[TBL] [Abstract][Full Text] [Related]
6. Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins.
Zhang L; Donda A
Methods Mol Biol; 2021; 2388():175-180. PubMed ID: 34524672
[TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
8. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.
Lawson V
Immunology; 2012 Sep; 137(1):20-7. PubMed ID: 22734667
[TBL] [Abstract][Full Text] [Related]
9. Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.
Zhang L; Donda A
Front Immunol; 2017; 8():1417. PubMed ID: 29163493
[TBL] [Abstract][Full Text] [Related]
10. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.
Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; Hooijberg E; Kramer D; Reurs AW; van den Eertwegh AJ; von Blomberg BM; Scheper RJ; Bontkes HJ
J Immunol; 2008 Aug; 181(4):2446-54. PubMed ID: 18684935
[TBL] [Abstract][Full Text] [Related]
12. The GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner.
Pereira CS; Ribeiro H; Pérez-Cabezas B; Cardoso MT; Alegrete N; Gaspar A; Leão-Teles E; Macedo MF
Mol Genet Metab; 2018 Sep; 125(1-2):161-167. PubMed ID: 30030044
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody.
Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408
[TBL] [Abstract][Full Text] [Related]
14. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
15. Novel in vitro invariant natural killer T cell functional assays.
Balasko A; Graydon C; Fowke KR
J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
[TBL] [Abstract][Full Text] [Related]
16. Murine CD8
Oh S; Lee H; Shin JH; Hong C; Park SH
Immunol Invest; 2018 Jan; 47(1):89-100. PubMed ID: 29099628
[TBL] [Abstract][Full Text] [Related]
17. Function and expression of CD1d and invariant natural killer T-cell receptor in the cotton rat (Sigmodon hispidus).
Fichtner AS; Paletta D; Starick L; Schumann RF; Niewiesk S; Herrmann T
Immunology; 2015 Dec; 146(4):618-29. PubMed ID: 26346465
[TBL] [Abstract][Full Text] [Related]
18. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
19. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.
Zeng J; Wang S
Stem Cells Transl Med; 2014 Jan; 3(1):69-80. PubMed ID: 24292792
[TBL] [Abstract][Full Text] [Related]
20. Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes.
Arora P; Kharkwal SS; Ng TW; Kunnath-Velayudhan S; Saini NK; Johndrow CT; Chang YT; Besra GS; Porcelli SA
Chem Phys Lipids; 2015 Oct; 191():75-83. PubMed ID: 26306469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
